The Next Generation Sequencing Market size was estimated USD 6.8 billion in 2022 and is expected to reach USD 32.7 billion by 2030 at a CAGR of 21.7% during the forecast period of 2023-2030.    

The Next Generation Sequencing (NGS) market is poised for exponential growth in the coming years. With advancements in technology and decreasing costs, NGS has become more accessible to researchers, clinicians, and pharmaceutical companies alike. This revolutionary technique allows for rapid and accurate sequencing of DNA and RNA, enabling a deeper understanding of genetic variations, disease mechanisms, and personalized medicine.

One of the key drivers of the NGS market is the increasing demand for precision medicine. As healthcare providers strive to deliver tailored treatments based on an individual's genetic makeup, NGS plays a crucial role in identifying specific gene mutations or biomarkers associated with diseases. This information helps in predicting disease progression, selecting appropriate therapies, and monitoring treatment response.

Get Free PDF Sample Report: https://www.snsinsider.com/sample-request/3720

Moreover, the application of NGS extends beyond human health. It has found significant utility in agriculture, environmental research, forensics, and animal breeding. The ability to sequence entire genomes quickly and cost-effectively has opened up new avenues for studying plant genetics, biodiversity conservation, tracking infectious diseases NGS technology has revolutionized various fields by providing valuable insights into genetic variations, population dynamics, and evolutionary patterns.

NGS technology has also played a crucial role in advancing personalized medicine. By analyzing an individual's genetic makeup, healthcare professionals can now tailor treatment plans to specific genetic variations, improving patient outcomes and reducing adverse reactions. Additionally, NGS has paved the way for groundbreaking discoveries in cancer research. The ability to identify genetic mutations associated with different types of cancer has led to the development of targeted therapies, offering new hope for patients and potentially revolutionizing the field of oncology. Furthermore, NGS has proven invaluable in studying microbial communities and their impact on human health. By sequencing the genomes of various microorganisms, scientists can better understand the role of these microbes in diseases and develop strategies to manipulate them for therapeutic purposes. The applications of NGS continue to expand, promising exciting advancements in various scientific disciplines.

KEY MARKET SEGMENTS

By Product

·         Consumables

o    Sample Preparation

o    Target Enrichment

o    Others

·         Platforms

o    Sequencing

o    Data Analysis

 By Technology

·         WGS

·         Whole Exome Sequencing

·         Targeted Sequencing & Resequencing

o    DNA-based

o    RNA-based

By Workflow

·         Pre-Sequencing

o    NGS Library Preparation Kits

o    Semi-automated Library Preparation

o    Automated Library Preparation

·         Sequencing

·         NGS Data Analysis

o    NGS Primary Data Analysis

o    NGS Secondary Data Analysis

o    NGS Tertiary Data Analysis

By Application

·         Oncology

o    Diagnostics and Screening

§  Oncology Screening

§  Sporadic Cancer

§  Inherited Cancer

§  Companion Diagnostics

§  Other Diagnostics

o    Research Studies

·         Clinical Investigation

o    Infectious Diseases

o    Inherited Diseases

o    Idiopathic Diseases

o    Non-Communicable/Other Diseases

·         ReProduct & Serviceive Health

o    NIPT

§  Aneuploidy

§  Microdeletions

o    PGT

§  Newborn Genetic Screening

§  Single Gene Analysis

·         HLA Typing/Immune System Monitoring

·         Metagenomics

·         Epidemiology & Drug Development

·         Agrigenomics & Forensics

·         Consumer Genomics

By End User

·         Academic Research

·         Clinical Research, Hospitals & Clinics

·         Pharma & Biotech Entities

·         Other Users

Major Players Listed in the Report are as Follows:

Illumina, F. Hoffman-La Roche Ltd., QIAGEN, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Oxford Nanopore Technologies, PierianDx, Genomatix GmbH, DNASTAR, Inc., Perkin Elmer, Inc., Eurofins GATC Biotech GmbH, BGI, and Others.

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand – Head of Business Development & Strategy,

info@snsinsider.com,

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)